PRR13 and neoplasm: Patients with low TXR1 expression experienced a longer PFS (5.5 vs 3.0 months; P=0.029; Figure 1B), OS (19.1 vs 10.0 months; P=0.003; Figure 2B) and RR (45 vs 18%, P=0.018) when compared with patients whose tumours had high TXR1 mRNA expression.